Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPTN 106: Rectal and Oral Tenofovir-Based PrEP
NCT06560684Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tenofovir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2024; status: completed.
02
Drugs
tenofovir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06560684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560684.